Academic Collaborations as an Important Anchor for BMS
September 18, 2018
Time: 11:30 AM - 2:15 PM
Please join our sponsor for a Lunch & Learn panel on tackling tough science: Bristol-Myers Squibb leaders talk about academic collaborations as an important anchor for its new Cambridge site.
Bristol-Myers Squibb will open its new research facility in Cambridge later this year. With a fully integrated drug discovery and translational medicine organization, the site will focus on novel targets and pathways for tumors that are refractory to current Immuno-Oncology therapies, and implement our discovery platforms across all of our therapeutic areas of focus (oncology, cardiovascular disease, immunoscience, and fibrosis). This panel explores how the Cambridge based team, and the broader BMS organization, intends to work collaboratively with local academic experts to tackle some of the toughest scientific problems in oncology, and in drug discovery and development more generally. Drawing on the long history Bristol-Myers Squibb has had of working with academics to drive innovation, the panelists will highlight concrete examples from existing translational research and drug discovery focused collaborations. They will also explore program ideas leveraging BMS’ expertise and technology, as mechanisms to engage further with the local academic community. Investigators from clinical and research based institutions are encouraged to join this conversation!
- Litao Zhang, Vice President, Lead Discovery and Optimization, Discovery
- Michaela Bowden, Director, Translational Biology, Translational Medicine
- Rick Ewing, Head External Partnerships, Discovery Chemistry and Molecular Technologies, Discovery
- Moderated by Sharon Cload, Vice President, Molecular Discovery Technologies, Discovery
11:30 AM | Registration Opens, Networking and Lunch
12:15 PM | Panel Discussion
1:30 PM | Q&A, Networking
2:15 PM | Program Close